Pemetrexed
- Research compound
- Still being tested
- Identity checked
- Sources last checked 2026-09-04
This page shows what was measured, who it was measured in, and what that does not settle.
What Pemetrexed does in the body
Recurrent, metastatic non-squamous, NSCLC after prior chemotherapy
From the FDA-approved label: Pemetrexed for injection is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
- Where it acts
- Not recorded.
- Kind of result
- No result is published, so no kind of result applies yet
- Supervision
- Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · F4GSH45R4C · read 2026-08-29
Its recorded molecular formula is C20H19N5Na2O6, weighing 516.41.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 110 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What is missing or unclearRead from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
- PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.
Who is missing from the studies
- Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of pemetrexed in pediatric patients have not been established.”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
On older people, the label states: “Of the 3,946 patients enrolled in clinical studies of pemetrexed, 34% were 65 and over and 4% were 75 and over.”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on findings from animal studies and its mechanism of action, pemetrexed can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 ) ] .”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of pemetrexed or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
Where the result stopped carrying
- This is a scope explorer, not a diagnosis engine.
- It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to takeRead from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
- It was studied for a different goal
- The studies measured something else entirely. Nothing in this record points to this reason.
- A different form was studied
- The studied form is not the form on the shelf. Nothing in this record points to this reason.
- There was nothing to correct
- Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
- Something else had to happen too
- In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
- The change is too small to feel
- A real change can still sit below what a person notices. Nothing in this record points to this reason.
- Day-to-day swing hides it
- Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
- Not enough time yet
- The studies ran longer than the person has waited. Nothing in this record points to this reason.
- It was not taken as studied
- Missed days change the result, and studies count them. Nothing in this record points to this reason.
- Something else changed at the same time
- Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
- The product may not be what it says
- Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
- No recorded reason
- RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to takeRead from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Still being tested
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravenous
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as injection, powder, lyophilized, for solution, injection, powder, for solution, injection, given by the intravenous route.
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to takeNothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclearRead from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravenous
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
35 products list this as an active ingredient in the United States drug directory. 35 of them contain it and nothing else.
FDA National Drug Code directory · 67184-0504 · read 2026-08-29
They are sold as injection, injection, powder, for solution, injection, powder, lyophilized, for solution and powder, taken intravenous.
FDA National Drug Code directory · 67184-0504 · read 2026-08-29
The regulator's established pharmacologic class for it is folate analog metabolic inhibitor [epc] and folic acid metabolism inhibitors [moa].
FDA National Drug Code directory · 67184-0504 · read 2026-08-29
14 published labels name it as an active ingredient. 14 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-29
190 marketed supplement labels list this ingredient, classed as non-nutrient/non-botanical.
NIH Dietary Supplement Label Database · 252358 · read 2026-08-29
Those labels carry all other and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
NIH Dietary Supplement Label Database · 252358 · read 2026-08-29
PEMRYDI RTU is intravenous at 3., recorded as fda label in effect 2025-07-08 in the United States.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to takeRead from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine, investigational agent. The questions below are for a clinician or pharmacist.
Questions worth asking
- Which of the trials of Pemetrexed studied people like me?
- What was measured, and for how long?
- Was the result a laboratory value or a health outcome?
- What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclearRead from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Pemetrexed are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in peopleRead from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
- FDA substance identifier (UNII)
- F4GSH45R4C
- CAS registry number
- 357166-30-4
- PubChem compound
- 135564527
- RxNorm concept
- 2056898
- EMA substance identifier
- 100000159976
- DrugBank
- DBSALT001782
Checks this page had to pass
Passed
Identity resolved
no open identity hold
Passed
No unresolved merge across substance families
no quarantine open
Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
Passed
Canonical metadata present
slug and display name present
What is missing or unclearRead from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
The earliest marketing start date recorded for a listed product is 20040204.
FDA National Drug Code directory · 67184-0504 · read 2026-08-29
What is missing or unclearRead from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
- Were people like me actually studied?
- How close is this evidence to something I would notice?
- What does nobody know about this yet?
- What is a biomarker?
This order is fixed in code and does not count clicks or time on the page.
What is not here
10 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
- What was measured, goal by goal — found nothing in the sources checked.
- What happened in people — found nothing in the sources checked.
- How close this is to real life — found nothing in the sources checked.
- The path through the body — found nothing in the sources checked.
- Felt, measured, or meaningful — found nothing in the sources checked.
- How long anything takes — found nothing in the sources checked.
- What it may clash with — found nothing in the sources checked.
- Other ways to the same goal — found nothing in the sources checked.
- Claims that go past the evidence — found nothing in the sources checked.
- What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
On the Pemetrexed label: indicated for what?
"Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with…": indications and usage on Pemetrexed's label. DailyMed label · 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e · 2026-08-21
928 registered trials of Pemetrexed — at which phases?
- Registered studies posting no result
- 619 of 928
928 registered studies of Pemetrexed: 541 phase2, 231 phase1, 215 phase3, 16 phase4, 14 na, 11 na or unstated, 5 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
0 with a PubMed record
Show the evidence
- phase2541
- phase1231
- phase3215
- phase416
- na14
- na or unstated11
11 more recorded rows
- early phase15
- completed394
- recruiting132
- terminated132
- active not recruiting99
- unknown98
- withdrawn39
- not yet recruiting29
- suspended3
- approved for marketing1
- enrolling by invitation1
recorded 2026-09-01 · last checked 2026-09-04
159 of Pemetrexed's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, sponsor decision unspecified, other?
safety (17), futility/efficacy (17), accrual/recruitment (51), funding/business (20), sponsor decision unspecified (6) and other (48): Pemetrexed's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"lack of acurral"; 159 of 928 registered studies
Show the evidence
Trial
- NCT00165503terminated; "lack of acurral"
- NCT00203931terminated; "Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed after first-line therapy"
- NCT00216216terminated; "The results from the interim analysis were not favorable to continue this trial."
- NCT00259285terminated; "Trial was stopped early due to low enrollment."
- NCT00265785terminated; "Closed due to poor accrual"
- NCT00268437terminated; "Trial closed early because, during an interim analysis, the primary endpoint fell short."
14 further recorded trials
- NCT00280748terminated; "Slow accrual"
- NCT00290017terminated; "FDA Hold May 2007"
- NCT00310050terminated; "slow accrual"
- NCT00321308terminated; "See Termination Reason in Detailed Description."
- NCT00351039terminated; "slow accrual"
- NCT00356525terminated; "Stopped early due to low enrollment"
- NCT00369629terminated; "This was planned as a phase I/II study originally, but due to a lack of funding, the phase II portion was never conducted."
- NCT00383266terminated; "Low accrual"
- NCT00383331terminated; "Trial was stopped early due to low enrollment"
- NCT00389688terminated; "low accrual"
- NCT00394147terminated; "stopped for lack of efficacy"
- NCT00402883terminated; "Terminated due to bevacizumab and chemoradiotherapy toxicity"
- NCT00438204terminated; "All data collection has completed."
- NCT00447421terminated; "Interim results of another trial showed inferior activity of treatment"
recorded 2026-09-01 · last checked 2026-09-04
Human studies of Pemetrexed used Pemetrexed 500 mg/m2 — over how long?
studies of Pemetrexed used the recorded amount. ClinicalTrials.gov · 2026-09-01
6 recorded entries; human; also "Pemetrexed 500 mg/m2", "Pemetrexed 1000 mg/m2", "Pemetrexed 500 mg/m^2"
Show the evidence
human
- NCT00191191Pemetrexed 500 mg/m2
- NCT00191191Pemetrexed 1000 mg/m2
- NCT02862457Pemetrexed 500 mg/m^2
- NCT03110484Pemetrexed 500 MG
- NCT05244837pemetrexed 500mg/m2
- NCT05299125Pemetrexed 500 mg
recorded 2026-09-01 · last checked 2026-09-04
Pemetrexed's half-life is 3.5 hours — which schedules were studied?
3.5 hours, the half-life Pemetrexed's label states: "Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min)." DailyMed label · 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e · 2026-08-21
Show the evidence
- half life pharmacokinetics3.5 hours; Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- metabolism pharmacokineticsMetabolism Pemetrexed is not metabolized to an appreciable extent.
recorded 2026-08-21 · last checked 2026-09-04
Which running trial of Pemetrexed could settle lifespan?
NCT03351842 measures Disease-Free-Survival-Rate, reading out 2024-09-01.
95 open trials; n 460; "Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%"
Show the evidence
Trial
- NCT03351842"Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%"; n 460; "Disease-Free-Survival-Rate"; 2024-09-01
- NCT06497543"Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic"; n 80; "Overall Survival"; 2026-04-30
- NCT06927986"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）"; n 380; "Progression-free survival (PFS) assessed by independent review committee (IRC)"; 2026-08-30
- NCT05184712"Phase 3 Clinical Study of AK112 for NSCLC Patients"; n 322; "Progression-free survival (PFS)"; 2026-09
- NCT04892953"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy"; n 51; "Progression free survival (PFS)"; 2026-09-30
- NCT05870319"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients"; n 376; "Progression-free survival (PFS)"; 2026-09-30
14 further recorded trials
- NCT05689671"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma"; n 136; "Overall Survival (OS)"; 2026-10
- NCT03425643"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)"; n 797; "Event Free Survival (EFS)"; 2026-10-15
- NCT04129502"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations"; n 354; "Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1"; 2026-10-31
- NCT05281406"Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)"; n 50; "Progression Free Survival (PFS1)"; 2026-11
- NCT05261399"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment"; n 341; "Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib."; 2026-11-23
- NCT05990127"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer"; n 642; "Overall Survival(OS)"; 2026-11-28
- NCT04166487"Plasma-Adapted First-Line Pembro In NSCLC"; n 40; "6-month Progression Free Survival rate"; 2026-12-01
- NCT04966663"Using ctDNA to Determine Therapies for Lung Cancer"; n 66; "Relapse Free Survival"; 2026-12-01
- NCT06396065"Phase III Study of AK112 for NSCLC Patients"; n 420; "Progression-free survival (PFS)"; 2026-12-31
- NCT05754853"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer"; n 290; "Overall Survival (OS)"; 2027-01
- NCT04267848"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])"; n 1210; "Disease free survival (DFS)"; 2027-01-31
- NCT05766800"Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer"; n 100; "Event-free survival (EFS)"; 2027-04-01
- NCT05715229"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy"; n 108; "Progression Free Survival (PFS)"; 2027-04-28
- NCT06440954"Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases"; n 220; "Intracranial progression-free survival (I-PFS)"; 2027-04-30
Which 151 trials of Pemetrexed posted no result?
- Posted no result
- 151 of 151 completed trials
- Registrations
- NCT00005636, NCT00003706, NCT00051493, NCT00003711, NCT00489983 and NCT00490373, and 145 more
- Completion dates
- oldest 2000-11; newest 2024-08-16
Show the evidence
Trial
- NCT000056362000-11
- NCT000037062002-06
- NCT000514932002-12
- NCT000037112004-09
- NCT004899832005-03
- NCT004903732005-04
14 further recorded trials
- NCT000655332005-06
- NCT000728652005-09
- NCT001908012005-09
- NCT001908402005-10
- NCT001907622005-11
- NCT001913472005-11
- NCT001915032005-11
- NCT000614642006-02
- NCT001914122006-03
- NCT000798722006-05
- NCT001920882006-05
- NCT001018422006-07
- NCT000711362006-08
- NCT002515502006-08
At the median, Pemetrexed's trials enrolled 72 people — anything larger?
- Median enrolment
- 72
- Largest enrolment
- 12000
- Registered trials counted
- 914
What do 4406 spontaneous reports say about Pemetrexed — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Pemetrexed appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 4406 reaction mentions were counted: anaemia 675; vomiting 518; malignant neoplasm progression 510; neutropenia 502. FAERS via Open Targets · CHEMBL225072 · 2026-06-24
Show the evidence
- anaemia675
- vomiting518
- malignant neoplasm progression510
- neutropenia502
- thrombocytopenia500
- pancytopenia410
4 more recorded rows
- acute kidney injury349
- disease progression345
- febrile neutropenia316
- decreased appetite281
recorded 2026-06-24 · last checked 2026-09-04
Which 10 reactions does Pemetrexed's label not list?
acute kidney injury, anaemia and decreased appetite and 7 more reported for Pemetrexed, absent from its label. FAERS via Open Targets · CHEMBL225072 · 2026-06-24
2 label terms; 10 reported and unlisted; 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e
Show the evidence
- acute kidney injurycount not stated
- anaemiacount not stated
- decreased appetitecount not stated
- disease progressioncount not stated
- febrile neutropeniacount not stated
- malignant neoplasm progressioncount not stated
4 more recorded rows
- neutropeniacount not stated
- pancytopeniacount not stated
- thrombocytopeniacount not stated
- vomitingcount not stated
recorded 2026-06-24 · last checked 2026-09-04
Pemetrexed and OAT3, OAT4 and TRANSPORTER: shared by which compounds?
OAT3, OAT4 and TRANSPORTER appear in Pemetrexed's recorded interaction sentences, 8 in all. DailyMed label · 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e · 2026-08-21
CYP1A2, CYP2C9, CYP2D6, CYP3A, OAT3, OAT3; 7 shared nodes; pharmacokinetics
Show the evidence
Interaction statement
- pharmacokineticsIn vitro studies indicated that pemetrexed is a substrate of OAT3 (organic anion transporter 3), a transporter that is involved in the active secretion of pemetrexed.
- pharmacokineticsDrug Interaction Studies Drugs Inhibiting OAT3 Transporter Ibuprofen, an OAT3 inhibitor, administered at 400 mg four times a day decreased the clearance of pemetrexed and increased its exposure (AUC) by approximately 20% in patients with normal renal function (creatinine clearance >80 mL/min).
- pharmacokineticsIn Vitro Studies Pemetrexed is a substrate for OAT3.
- pharmacokineticsIbuprofen, an OAT3 inhibitor inhibited the uptake of pemetrexed in OAT3-expressing cell cultures with an average [I u ]/IC 50 ratio of 0.38.
- pharmacokineticsIn vitro data predict that at clinically relevant concentrations, other NSAIDs (naproxen, diclofenac, celecoxib) would not inhibit the uptake of pemetrexed by OAT3 and would not increase the AUC of pemetrexed to a clinically significant extent.
- pharmacokineticsPemetrexed is a substrate for OAT4.
2 more recorded rows
- Interaction statement pharmacokineticsIn vitro, ibuprofen and other NSAIDs (naproxen, diclofenac, celecoxib) are not inhibitors of OAT4 at clinically relevant concentrations.
- Interaction statement pharmacokineticsDrugs Metabolized by Cytochrome P450 Enzymes In vitro studies suggest that pemetrexed does not inhibit the clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.
- CYP1A2FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Golodirsen, Tinidazole
- CYP2C9FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Tinidazole, Naldemedine
- CYP2D6FINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Fluoxetine
- CYP3AFINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, Vincristine, Naldemedine, Eravacycline, Rasburicase, Repotrectinib, Prucalopride
OAT3
- TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Deoxycholic acid, Golodirsen, Naldemedine, Eravacycline, Prucalopride
- TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Deoxycholic acid, Golodirsen, Naldemedine, Eravacycline, Prucalopride
- TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Deoxycholic acid, Golodirsen, Naldemedine, Eravacycline, Prucalopride
recorded 2026-08-21 · last checked 2026-09-04
Where it is registered
Identifiers, relations and other names
The exact record
- UNII
- 236Y2F7D9J
- ChEMBL id
- CHEMBL225072
- PubChem CID
- 135565230
- CAS number
- 182009-04-7
- RxCUI
- 2590669
- InChIKey
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
- Trade name
- Alimta, Pemfexy, Pemetrexed baxter, Pemetrexed lilly, Pemetrexed sandoz, Pemetrexed pfizer (previously known as pemetrexed hospira uk limited), Pemetrexed fresenius kabi, Ciambra, Pemetrexed accord, Pemetrexed krka, Pemetrexed medac, Pemrydi Rtu
- Development code
- LY-231514, LY231514, NSC-698037
- Also called
- pem, PEMETREXED DISODIUM, PEMETREXED TROMETHAMINE, Pemetrexed ditrometamol, Pemetrexed ditromethamine, PEMETREXED MONOHYDRATE, Armisarte, PEMETREXED DIPOTASSIUM, PEMETREXED DISODIUM HEMIPENTAHYDRATE, Pemetrexed monohydrate [WHO-DD]
- Salt form
- LY-231514 DISODIUM SALT, LY231514 DISODIUM SALT, Pemetrexed disodium heptahydrate, Pemetrexed sodium hydrate, Pemetrexed sodium salt, pemetrexed disodium for injection, Pemetrexed ditromethamine dihydrate, Pemetrexed tromethamine anhydrous, Pemetrexed diacid monohydrate, Pemetrexed sodium hemipentahydrate
Sources (6)
Sources
- chembl+drugsfda+ema chembl+drugsfda+ema ·
- CLINICALTRIALS_SNAPSHOT K1:04Q9AIZ7NO ·
- ClinicalTrials.gov clinicaltrials.gov ·
- DailyMed label 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e ·
- FAERS via Open Targets CHEMBL225072 ·
- Drugs@FDA K1:04Q9AIZ7NO ·
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
How these records are assembled · Which registers were checked
Index-quality checks
- identity passed: no open identity hold
- required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
- public claims reviewed: 0 reviewed claim(s); drafts are never rendered
- source coverage passed: 6 source rows
- no critical contamination: no quarantine open
- canonical metadata passed: slug and display name present
- no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.